StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report sent to investors on Sunday morning. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of NYSE NAVB opened at $0.00 on Friday. Navidea Biopharmaceuticals has a twelve month low of $0.00 and a twelve month high of $0.13. The firm has a market cap of $100,084.00, a PE ratio of -0.02 and a beta of 1.46.
About Navidea Biopharmaceuticals
Want More Great Investing Ideas?
Further Reading
- Five stocks we like better than Navidea Biopharmaceuticals
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Momentum Trades for October With Ample Upside Ahead
- Stock Splits, Do They Really Impact Investors?
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Using the MarketBeat Dividend Yield Calculator
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.